On October 9, 2025, aTyr Pharma, Inc. was sued for violations of the federal securities laws in the United States District Court for the Southern District of California on behalf of investors who purchased or otherwise acquired aTyr common stock between January 16, 2025, and September 12, 2025, inclusive (the “Class Period”).
We use cookies to improve your overall web experience. By using our website, you consent to the use of cookies in accordance with our Privacy Policy.